Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 14/20 | 0.47 |
| ▸ | CASP1 | P29466 | 13/20 | 0.47 |
| ▸ | CASP7 | P55210 | 13/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 13/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.47 |
| ▸ | MEN1 | O00255 | 11/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.47 |
| ▸ | BRCA1 | P38398 | 3/20 | 0.47 |
| ▸ | HBB | P68871 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2983353 | 0.91 | SCN9A (0.55) | USP2CASP1CASP7CYP1A2CYP3A4 | |
| SCHEMBL2974989 | 0.90 | ADORA1 (0.43) | USP2CASP1CASP7CYP1A2CYP3A4 | |
| SCHEMBL2971703 | 0.89 | ADORA1 (0.49) | USP2CASP1CASP7CYP1A2CYP3A4 | |
| SCHEMBL2986078 | 0.89 | ADORA1 (0.56) | USP2CASP1CASP7CYP1A2CYP3A4 | |
| SCHEMBL2982979 | 0.89 | ADK (0.43) | USP2CASP1CASP7CYP1A2CYP3A4 | |
| SCHEMBL2989049 | 0.89 | SCN9A (0.52) | USP2CASP1CASP7CYP1A2CYP3A4 | |
| SCHEMBL2982038 | 0.89 | ADORA1 (0.47) | USP2CASP1CASP7CYP1A2CYP3A4 | |
| SCHEMBL2977453 | 0.89 | ADORA1 (0.47) | USP2CASP1CASP7CYP1A2CYP3A4 | |
| SCHEMBL2983029 | 0.88 | ADORA1 (0.46) | USP2CASP1CASP7CYP1A2CYP3A4 | |
| SCHEMBL2984782 | 0.87 | ADORA1 (0.46) | USP2CASP1CASP7CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831207-B1 | AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-7858785-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7786132-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-1831207-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | AMGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2006066172-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PLK1, TYMP, TK2 | USP2 3167/4885CASP1 2189/4885CASP7 2581/4885 |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | PLK1, TYMP, TK2 | USP2 3167/4885CASP1 2189/4885CASP7 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.